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ABSTRACT  
Background: Natural products have been studied regarding their effectiveness on 
Inflammatory Bowel Disease (IBD).  
Hypothesis/Purpose: To examine the effects of Mastiha (Pistacia lentiscus var. Chia) on 
clinical course and amino acid (AA) profile of patients in remission. 
Study design: This is a randomised, double-blind, placebo-controlled clinical trial. 
Methods: Patients (N = 68) were randomLy allocated to Mastiha (2.8g/day) or placebo 
adjunct to sTable medication. Free AAs were identified applying Gas Chromatography-Mass 
Spectrometry in plasma. Medical-dietary history, Inflammatory Bowel Disease Questionnaire, 
Harvey-Bradshaw Index, Partial Mayo Score, biochemical, faecal and blood inflammatory 
markers were assessed. Primary endpoint was the clinical relapse rate at 6 months. Secondary 
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endpoints included variations in free AAs, inflammatory biomarkers and quality of life. 
Statistical significance was set at 0.05. 
Results: Concerning AAs and biochemical data, alanine (p = 0.006), valine (p = 0.047), 
proline (p = 0.022), glutamine (p < 0.001) and tyrosine (p = 0.043) along with total 
cholesterol (p = 0.032) and LDL cholesterol (p = 0.045) increased only in placebo group 
compared with baseline and the change between the study groups was significantly different. 
Inflammatory markers had not a significantly different change between the two groups, even 
serum IL-6, faecal calprotectin and faecal lactoferrin increased only in the placebo group. 
Although Mastiha was not proven superior to placebo in remission rate (17.6% vs. 23.5%, p = 
0.549), attenuation in increase of free AAs levels in verum group is reported. 
Conclusion: Mastiha inhibited an increase in plasma free AAs seen in patients with quiescent 
IBD. Since change of AAs is considered an early prognostic marker of disease activity, this 
indicates a potential role of Mastiha in remission maintenance. 
 
(ClinicalTrials.gov Identifier: NCT02796339) 
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Mastiha, Remission 
 
Abbreviations: AA, amino acid; ALP, alkaline phosphatase; ANOVA, analysis of variance; 
CD, Crohn’s Disease; CRP, C-reactive protein; GC, gas chromatography; HBI, Harvey 
Bradshaw Index; IBD, Inflammatory Bowel Disease; IBDQ, Inflammatory Bowel Disease 
Questionnaire; IL, interleukin; LDH, lactate dehydrogenase; MedDiet, Mediterranean Diet; 
MS, mass spectrometry; PMS, Partial Mayo Score; SD, standard deviation; SGOT, glutamic-
oxaloacetic transaminase; SGPT, glutamic-pyruvic transaminase; SIM, selective ion 
monitoring; UC, Ulcerative Colitis; γ-GT, γ-glutamyl transferase. 
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1. Introduction 
Inflammatory Bowel Disease (IBD), including Crohn’s Disease (CD) and Ulcerative Colitis 
(UC) is a chronic ailment of the gastrointestinal tract with relapse and remission periods. 
Therapeutic strategies aim at induction and maintenance of remission, and although they have 
improved remission rates, long-term maintenance of remission without adverse effects 
remains challenging. (Neurath, 2017).  
Therefore, there is an increasing interest upon the role of plant-derived dietary supplements 
for IBD prevention and treatment, since they exhibit anti-inflammatory, immunoregulatory 
and antioxidant properties. Amongst others (i.e. curcumin, broccoli sprouts), there is clinical 
evidence showing promising effects on IBD for Mastiha (Farzaei et al, 2016). 
According to Eur. Ph. Monograph (01/2008:1876), Mastic or Mastiha is the dried resinous 
exudate from stems and branches of Pistacia lentiscus (Pistacia lentiscus L. var latifolius Coss 
or Pistacia lentiscus var. Chia). Since 2015 Mastiha is considered a traditional herbal 
medicinal product for mild dyspeptic disorders, symptomatic treatment of minor skin 
inflammations and healing of minor wounds (EMA, 2015). It is rich in terpenic acids 
(Assimopoulou and Papageorgiou, 2005), with antioxidant (Dedoussis et al, 2004), anti-
inflammatory (Heo et al, 2006) and cytotoxic (Balan et al, 2007) properties. Mastiha has been 
shown to be safe and effective in active CD (Kaliora et al, 2007a; 2007b). As an oleoresin, 
phenolic compounds have been detected in leaves and fruits of Pistacia lentiscus (Amel et al, 
2016), In general, phenolic compounds possess protective and therapeutic role in IBD through 
various mechanisms, such as down-regulation of inflammatory cytokines and enzymes 
(Farzaei et al, 2015). However, in this resin only simple phenols have been detected, however 
in low concentrations or even in traces (Kaliora et al, 2004). We have recently reported the 
absorption and bioavailability of the main triterpenic acids mastihadienonic and 
isomastihadienonic acids that have been identified in the highly active acidic fraction 
(Assimopoulou and Papageorgiou 2005; Papada et al, 2018; Paraschos et al, 2007; Xynos et 
al., 2018). Concentrations of these triterpenic compounds have been determined by Paraschos 
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and coworkers (2007); namely mastihadienonic acid 20.9mg/g mastiha and 
isomastihadienonic acid 19mg/g mastiha.  
Amino acids (AAs) play a key role in pathways regulating intestinal health, participating in 
protein synthesis, gene expression, intracellular protein turnover, oxidative stress and in 
stimulation of lymphocyte proliferation, inflammatory cytokines production and T cell-
mediated immunity (Li et al, 2007; Nakaya et al, 2014). AA profile differentiates in IBD and 
healthy pointing towards a link between AA profile and IBD. AAs are used as therapeutic 
options in order to maintain intestinal integrity in IBD (Liu et al, 2017). 
Based on the need for effective maintenance treatment without serious side effects and on the 
key role of AAs in remission maintenance, we aimed to investigate the effects of Mastiha on 
clinical course and plasma free AAs in quiescent IBD. 
 
2. Materials and methods  
2.1 Ethics and trial registration 
Harokopio University Ethics Committee reviewed and approved the protocol (49/29-10-2015) 
conducted according to the principles of Declaration of Helsinki and Tokyo for humans and 
Good Clinical Practice. The trial was registered with ClinicalTrials.gov (Identifier: 
NCT02796339). 
 
2.2 Participants 
Enrolment was initiated through the Hellenic Society of IBD patients. Confirmed patients, 
with biopsy proven UC or CD were enrolled based on certain criteria (Table 1). Detailed 
information about the study was provided and each patient agreeing to participate provided 
written Informed Consent. Recruitment lasted between May 2016 and March 2017 in Athens, 
Greece. Follow-up visits were completed by September 2017.  
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2.3 Study design 
This is a randomised, double-blind, placebo-controlled, parallel group clinical trial (Fig. 1). 
IBD patients were designated to be in remission from a Harvey Bradshaw Index (HBI) ≤ 4 
(CD) and Partial Mayo Score (PMS) ≤ 1 (UC) scored by experienced gastroenterologists. 
Since access to the patients full list was unavailable due to privacy policy of the Society, 
simple randomization was applied. After obtaining informed consent, the independent of the 
recruitment process contact would allocate participants to intervention. Randomisation was 
applied by a computer generated random number list prepared by an independent investigator. 
Blinding of all other staff, analysts and participants was strictly maintained. The Mastiha 
group received natural Mastiha at a dose of 2.8g daily (4 tabs x 700 mg Mastiha), while the 
placebo group received identical placebo Tablets for 6 months, as an adjunct to conventional 
medical treatment. The choice of this dose was based on a previous pilot study in CD patients 
experiencing no side effects and a bioavailability study in healthy humans (Kaliora et al. 
2007a, 2007b, Papada et al. 2018). Additionally, standard nutritional advice was provided and 
patients were encouraged to report adverse effects. The verum Tablets weighed 0.98g/Tablet 
and consisted of 70% Mastiha resin from the stems and brunches of Pistacia lentiscus var. 
Chia, 14% microcrystalline cellulose, 14% dibasic calcium phosphate anhydrous and 2% 
magnesium stearate. The resin was powdered prior to inclusion in Tablet and the powder 
obtained was off-white to barely yellowish. The placebo Tablets weighed 0.99g/Tablet and 
consisted of 49% microcrystalline cellulose with a characteristic off-white to yellowish colour 
for similarity to verum, 49% dibasic calcium phosphate anhydrous, and 2% magnesium 
stearate. In terms of odour similarity, the cap in placebo box was sprayed with the mastiha 
water obtained by steam distillation. The verum and placebo shared identical appearance and 
organoleptic characteristics. Production of Mastiha is conducted under a GMP process, and 
has been granted a manufacturer's license by the Natiοnal Organization for Medicines (EOF). 
Additionally, it is certified under the standards of ISO 9001:2008 for the elaboration, 
packaging and trade of Mastiha, and ISO 22000:2005, for the elaboration and packaging of 
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Mastiha. In studies using the present formulation, no natural impurities and related substances 
have been found in Mastiha above 0.5%. 
 
2.4 Baseline assessment 
2.4.1. Medical history: Medical history was recorded by a gastroenterologist, including 
general data as well as IBD-specific information. HBI was calculated for CD patients (Harvey 
and Bradshaw, 1980) and PMS for UC patients (Lewis et al, 2008). 
2.4.2. Anthropometric and dietary assessment: Body weight was measured to the nearest 
0.1kg and height was measured to the nearest millimeter twice. Body Mass Index was 
calculated. Compliance with Mediterranean diet was evaluated with MedDiet Score 
(Panagiotakos et al, 2006). 
2.4.3. Blood and stool sample collection: Standard blood sampling (20mL) was performed 
and stool samples were collected with a preparation system with extraction buffer IDK 
Extract® (Immundiagnostik, AG).  
2.4.4. Quality of life assessment: Quality of life was assessed with the validated Greek 
version of Inflammatory Bowel Disease Questionnaire (IBDQ) with higher scores indicating 
better quality of life (Guyatt et al, 1989; Pallis et al, 2001). 
 
2.5. Follow-up assessment 
There was a biweekly telephone contact with patients to check upon compliance and side 
effects. At the end of intervention, the full baseline assessment was repeated. 
 
2.6. Laboratory analyses 
2.6.1. Biochemical analyses: Iron (Fe), albumin, and plasma fibrinogen were quantified 
with an automatic biochemical analyzer at baseline and follow-up. Routine laboratory tests 
included lactate dehydrogenase (LDH), urea, glutamic-oxaloacetic transaminase (SGOT), 
glutamic-pyruvic transaminase (SGPT), γ-glutamyl transferase (γ-GT), alkaline phosphatase 
(ALP), total and direct bilirubin, amylase and a lipid profile. 
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2.6.2. Amino acid analysis: Free (physiological) plasma AAs were determined by gas 
chromatography-mass spectrometry (GC-MS), employing Phenomenex® EZ:faast kit. The 
procedure involves a solid phase extraction followed by derivatisation and subsequent 
liquid/liquid extraction. The derivatised AAs are then analyzed by GC-MS.  
An Agilent (Wallborn, Germany) series GC 6890 N gas chromatograph, coupled with an 
HP5973 Mass Spectrometer detector (EI, 70eV), split-splitess injector and an HP7683 
autosampler was used for analysis. An aliquot (2 μl) of derivatized samples was injected into 
GC at a split ratio of 1:15. AA separation was achieved using Phenomenex Zebron ZB-A AA 
analysis-dedicated column (length = 10m, internal diameter = 0.25mm, film thickness = 
25μm). The carrier gas was helium at a constant flow of 1.1 ml/min. The injector and transfer 
line temperatures were 250 and 340 °C, respectively. The initial oven temperature was 110 
°C, increased to 320 °C at 30 °C/min and held at 320 °C for 3min. A selective ion monitoring 
(SIM) GC-MS method was applied for detection of 26 AAs, based on the ±0.05 retention time 
presence of target and qualifier ions at the predetermined ratios. The retention times, target 
and qualifier ions of AAs, are shown in Table S1. Quantification was carried out employing 
norvaline as internal standard and constructing reference curves for each AAs by standard 
solutions. 
2.6.3. Evaluation of inflammation: IL-6 (R&D Systems, Inc.) and IL-10 (OriGene 
Technologies, Inc.) were assessed applying sandwich ELISA at baseline and follow-up. C-
reactive protein (CRP) was measured in serum. Calprotectin, lysozyme and lactoferrin were 
quantified in stool (Immundiagnostik, AG). 
 
2.7 Sample size determination and statistical analysis  
Sample size to detect the effect of verum over placebo was calculated on the assumption that 
10% on verum versus 40% on placebo would experience clinical relapse (in CD scoring HBI 
≥ 5 and in UC scoring PMS ≥ 2). As such, a sample size of 64 patients was required for a 
80% chance of detecting significance at 5% level (α = 0.05) (power 80%) (Pocock, 1983). To 
allow for a drop-out rate of 10%, the number was increased to 70 patients. The primary 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
9 
endpoint was clinical relapse rate over 6 months. Secondary endpoints were plasma free AAs 
profile, serum and faecal inflammatory biomarkers and quality of life. 
Continuous variables are presented with mean and standard deviation (SD). Quantitative 
variables are presented with absolute and relative frequencies. All analyses were conducted 
on intention-to-treat basis. For proportions comparison, chi-squared and Fisher’s exact tests 
were used. For means comparison between groups Student’s t-test was computed. To reduce 
the bias implicit in utilizing only complete cases, multiple imputation for all data was 
implemented. Differences in changes of study variables at follow up between the two groups 
were evaluated using repeated measurements analysis of variance (ANOVA). Variables with 
skewed distribution were log-transformed for analysis of variance. All p values reported are 
two-tailed. Statistical significance was set at 0.05 and analyses were conducted with SPSS 
(version 22.0). 
 
3. Results  
Sixty-eight IBD patients (N = 68) met our recruitment criteria. A total of 34 patients were 
randomised to the placebo group and 34 patients to the Mastiha group; 46 were diagnosed 
with CD and 22 with UC. Clinical, anthropometric and demographic characteristics are 
presented in Table S2. No adverse events affecting gastrointestinal, renal and hepatic systems 
were reported. 
We detected no significant differences in relapse rates between the groups at follow-up (Table 
2). Additionally, disease activity indices and IBDQ score did not alter significantly at follow-
up in either group. MedDiet score decreased significantly only in placebo group at follow-up, 
although the mean change was not different between the groups (Table 3). All biochemical 
markers assessed were within normal range. Serum albumin increased significantly in 
Mastiha, and the mean change differed significantly between the groups. Total and LDL 
cholesterol increased significantly in placebo but not in Mastiha arm, resulting in a significant 
difference of mean changes between the arms. Serum glucose decreased significantly, while 
LDH increased significantly in placebo (Table 4).  
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Alanine, glycine, alpha-aminobutyric acid, valine, leucine, allo-isoleucine, isoleucine, 
threonine, serine, proline, asparagine, phenylalanine, ornithine, tyrosine, tryptophane and 
cystine increased significantly in placebo, while in Mastiha changes were insignificant (Table 
5). The mean changes in alanine, valine, proline and tyrosine differed significantly between 
the groups. Glutamine increased significantly in placebo and decreased significantly in 
Mastiha, the mean change between the two arms being significant. Glutamic acid increased 
significantly in Mastiha. 
Levels of serum and faecal inflammatory markers are given in Table 6. Serum IL-6 increased 
significantly in placebo. Also, faecal calprotectin and lactoferrin increased significantly in 
placebo, while they remained unaffected in Mastiha. No significant difference in mean 
changes between the groups was identified for serum or faecal biomarkers. 
 
4. Discussion  
A plethora of natural supplements have been studied on regulating IBD activity and several 
mechanisms have been proposed for their beneficial properties such as anti-inflammatory, 
immunomodulatory and antioxidant effects, as well as enhancement of gut microbiota and 
modulation of intracellular transcription and transduction signaling pathways (Farzaei et al, 
2016). For example, curcumin and pomegranate extract have been investigated as potential 
treatment approach of intestinal inflammation (Camacho-Barquero et al, 2007; Larrosa et al, 
2010). However this is the first study on the effect of a natural product in modulation of AAs 
profile in IBD patients, to the best of our knowledge. 
Currently there are preclinical and clinical data supporting Mastiha’s beneficial effects on 
IBD (Gioxari et al, 2011; Kaliora et al, 2007a; 2007b; Papalois et al, 2012). However, for 
first, our study evaluates Mastiha in preventing IBD relapse on the basis of a Phase-II 
randomised placebo-controlled clinical trial. The relapse rates at 6 months (23.5% versus 
17.6%) with no significant differences between groups did not show that Mastiha was 
superior to placebo, but interesting results in free plasma AAs response were observed. AAs 
act as substrates and regulators in various metabolic paths. Different circulating AA profiles 
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have been reported in IBD reflecting nutritional state, but also inflammatory status and 
disease activity. For example, proline has been found upregulated in IBD patients (Hisamatsu 
et al, 2012) and valine has been found significantly increased in DSS-treated mice (Shiomi et 
al, 2011). 
We detected significant changes in valine and proline, and also in alanine, glutamine and 
tyrosine between the groups at follow up, significantly increasing in placebo arm, while 
remaining unchanged in Mastiha. Glutamine increased significantly in placebo and decreased 
significantly in Mastiha, the mean change between the arms being significant. Data on 
circulating AAs in inactive IBD are very limited, most deriving from studies in active disease 
or from experimental animals (Hisamatsu et al, 2012; Shiomi et al, 2011; Gupta et al, 2012; 
Zhang et al, 2013). However, Williams et al. (2012) found a significant decrease in serum 
alanine in inactive IBD patients, and although not investigated in their cohort, this was 
attributed to increased protein catabolism and intestinal permeability. A different AA profile 
was detected in IBD patients by Ooi et al. (2011), but presented data are on both active and 
inactive patients.
 
Increase in circulating AAs of our placebo patients is of considerable 
potential importance, as it may demonstrate the need for de novo AA synthesis in patients 
with increasing inflammation depicted by increased IL-6, faecal calprotectin and lactoferrin. 
Alanine and glutamine account for high proportion of total AAs in muscles and their efflux 
during catabolism might be reflected in plasma free AAs, proposed as a sensitive marker for 
early prognosis of catabolism and inflammation (Storr et al, 2013). Although no significant 
differences were detected in precursors of alanine (i.e. aspartic acid), it could be hypothesized 
that increased catabolism provides the nitrogen source and contributes to the carbon pool 
necessary for AAs synthesis. Mastiha treatment resulted in attenuation of the above-
mentioned increase in plasma AAs, indicative of a protective role in relapse onset. 
Additionally, unpublished data on plasma free AAs in healthy humans showed that plasma 
AAs decrease after Mastiha administration, and this correlates strongly with enhanced human 
antioxidant capacity (data not shown).  
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A significant increase was reported in albumin in verum group. Although albumin is a poor 
marker of nutritional status, its undoubted prognostic importance indicates advantage for 
Mastiha-treated patients. Additionally, total and LDL cholesterol significantly increased in 
the placebo compared to the verum group. Previous research showed that Mastiha lowers total 
cholesterol (Kartalis et al, 2016), which could be beneficial for IBD patients characterized by 
dyslipidemia and altered lipoprotein profile
 
(Sappati Biyyani et al, 2010) 
While our study has interesting results and the quality of being fully double-blinded, it has 
limitations, including absence of colonoscopy at follow-up, precluding our ability to comment 
on histological alterations and the absence of the full metabolic profile identification. The 
study was however very tightly controlled to ensure compliance with the protocol, and had a 
final power of 0.90 for the between-subjects main effect at an effect size of 0.37.  
Conclusively, although superiority of Mastiha versus placebo in remission maintenance in 
IBD was not confirmed, the amelioration in increased plasma AAs indicates a role in limiting 
disease activity. Future research upon the mechanism underlying the effects of Mastiha on 
modulation of amino acid profile in IBD is of interest. Identification of changes in the 
metabolome of IBD patients supplemented with Mastiha may indicate a plethora of 
metabolites (i.e. lipids, TCA intermediate metabolites etc) regulated by this natural product. 
We are confident that these results are of potential clinical significance and fully justify 
further exploration of Mastiha use in IBD. 
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Figure captions 
 
Fig. 1. Study design flowchart 
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TABLE 1. Inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
Sex: Male and Female Positive stool culture for enteric pathogens or 
Clostridium difficile toxin 
Age: 18-67 years old Antibiotic treatment during and 2 months 
prior to screening 
Inactive disease (>3 months)  
 Defined by HBI  ≤ 4 in CD 
 Defined by PMS  ≤ 1in UC 
Bowel surgery  ≤ 3 months prior to screening; 
a planned elective surgery or hospitalization 
during the study; clinically significant short 
bowel syndrome; presence of an intra-
abdominal abscess or a fistula with clinical or 
radiological evidence of an associated 
abscess; ileostomy; colostomy 
Childbearing age with a negative pregnancy 
test at eligibility and baseline assessment 
Enteral or Parenteral Nutrition; Alcohol or 
drug abuse, Vitamin or inorganic 
supplements, vegan or macrobiotic diet 
before and during the trial 
STable treatment with azathioprine or 
mesalamine and mesalamine analogues 
during the trial 
Any malignancy in the year prior to 
screening; cardiovascular disease; peptic 
ulcer 
 Pregnancy, lactation 
TABLE 2. Remission rate in placebo and verum group. Results are given as N(%) of 
total number. 
  Baseline Follow-up P 
  Placebo (34) Mastiha (34) 
 Baseline  0 (0.0) 0 (0.0) - 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
21 
Follow-up 8 (23.5) 6 (17.6) 0.549 
 
TABLE 3. Quality of life, disease activity indices and MedDiet scores at baseline and 
follow up. 
  Baseline Follow-up Change     
  Mean (SD) Mean (SD) Mean (SD) P
1
 P
2
 
IBDQ score           
Placebo  173.2 (24.8) 178.4 (23.5) 5.2 (22.0) 0.249 0.572 
Mastiha  180.1 (28.6) 181.7 (16.0) 1.6 (26.5) 0.720  
P
3
 0.290 0.496       
HBI
+‡
           
Placebo  2.24 (1.48) 2.70 (1.82) 0.46 (1.81) 0.355 0.436 
Mastiha  2.36 (1.25) 2.67 (2.14) 0.31 (1.88) 0.887 
 P
3
 0.567 0.805 
   PMS
++‡
           
Placebo  0.77 (0.44) 1.44 (1.37) 0.67 (1.16) 0.234 0.366 
Mastiha  0.67 (0.50) 0.76 (1.04) 0.10 (1.19) 0.857 
 P
3
 0.616 0.269 
   MedDiet Score      
Placebo  31.4 (6.2) 29.6 (6.2) -1.7 (4.6) 0.036 0.426 
Mastiha  30.3 (5.5) 29.6 (4.9) -0.7 (5.6) 0.438  
P
3
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1
p-value for time effect; 
2
Effects reported include differences between the groups in 
mean changes (repeated measurements ANOVA);
 3
p-value for group effect; 
‡
based on 
logarithmic transformations;
 +
 in CD patients; 
++
in UC patients.
TABLE 4. Biochemical data at baseline and at follow-up. 
  Baseline Follow-up Change     
  Mean (SD) Mean (SD) Mean (SD) P
1
 P
2
 
Plasma fibrinogen (mg/dL)
‡
       
Placebo  247.5 (62.8) 225.3 (51.0) -22.2 (70.1) 0.109 0.879 
Mastiha  264 (70.6) 242.8 (57.3) -21.2 (72.1) 0.080 
 
P
3
 0.295 0.191 
   
Serum Fe (μg/dL)‡         
Placebo  72.4 (34.6) 73.7 (25.3) 1.3 (36.9) 0.534 0.912 
Mastiha  73 (63.8) 71.2 (30.5) -1.8 (67.7) 0.437 
 
P
3
 0.618 0.621 
   
Serum albumin (g/dL)
‡
         
Placebo  4.38 (0.35) 4.36 (0.54) -0.02 (0.48) 0.639 0.016 
Mastiha  4.32 (0.3) 4.61 (0.49) 0.28 (0.56) 0.004 
 
P
3
 0.482 0.049 
   
Serum glucose (mg/dL)      
Placebo  87.1 (18.1) 77.9 (15.2) -9.2 (21.4) 0.004 0.204 
Mastiha  85.7 (13.5) 82.1 (10.4) -3.6 (13.5) 0.246  
 P
3
 0.728 0.186    
Total cholesterol (mg/dL)
‡
      
Placebo  171.7 (43.7) 188.8 (46.9) 17 (39.9) 0.004 0.032 
Mastiha  178.5 (42.6) 175.9 (32.9) -2.6 (29.6) 0.916  
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 P
3
 0.453 0.262    
LDL cholesterol (mg/dL)
‡
      
Placebo  96.4 (38.4) 111.4 (39.5) 15.1 (33.3) 0.002 0.045 
Mastiha  106.4 (36.6) 105.7 (27.3) -0.7 (25.9) 0.693  
 P
3
 0.173 0.744    
Serum amylase (IU/L)
‡
         
Placebo  68 (24.2) 69.3 (16.1) 1.3 (24) 0.351 0.124 
Mastiha  71.1 (24.7) 64.4 (11.4) -6.7 (21.3) 0.211 
 
P
3
 0.562 0.221 
   
Serum urea (mg/dL)         
Placebo  30.7 (7.7) 31.2 (6.3) 0.5 (8.3) 0.703 0.242 
Mastiha  32.5 (7.2) 30.8 (4.7) -1.7 (6.7) 0.202 
 
P
3
 0.326 0.777 
   
Serum LDH (U/L)
‡
       
Placebo  149.7 (33.7) 165.1 (36.2) 15.4 (35.4) 0.015 0.463 
Mastiha  146.8 (27.8) 154.7 (26) 7.9 (31.1) 0.150 
 
P
3
 0.765 0.292 
   
Serum total bilirubin (mg/dL)
‡
       
Placebo  0.40 (0.31) 0.42 (0.59) 0.20 (0.63) 0.100 0.112 
Mastiha  0.39 (0.22) 1.24 (3.25) 0.85 (3.25) 0.217 
 
P
3
 0.663 0.077 
   
Serum direct bilirubin (mg/dL)
‡
       
Placebo  0.18 (0.1) 0.18 (0.17) 0 (0.16) 0.106 0.965 
Mastiha  0.18 (0.1) 0.2 (0.21) 0.02 (0.2) 0.119 
 
P
3
 0.707 0.870 
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Serum SGOT (IU/L)
‡
       
Placebo  16.8 (4.5) 18.1 (4.5) 1.3 (6.1) 0.166 0.744 
Mastiha  18.2 (9.6) 19.2 (5.7) 1 (8.4) 0.067 
 
P
3
 0.813 0.410 
   
Serum SGPT (IU/L)
‡
         
Placebo  19.6 (10.5) 16.9 (6.9) -2.7 (9.7) 0.190 0.114 
Mastiha  17.1 (9.1) 17.1 (5.7) 0.1 (7) 0.350 
 
P
3
 0.249 0.675 
   
Serum γ-GT (IU/L)‡         
Placebo  18.3 (10.3) 19.2 (8.4) 0.9 (11.4) 0.356 0.955 
Mastiha  29.3 (72.4) 26.7 (49.6) -2.6 (25.4) 0.317 
 
P
3
 0.799 0.723 
   
Serum ALP (IU/L)
‡
     
Placebo  65.4 (19) 69.2 (16.5) 3.8 (20.2) 0.217 0.642 
Mastiha  67.8 (41) 73 (39.3) 5.2 (19.1) 0.061 
 
P
3
 0.780 0.870 
   
1
p-value for time effect; 
2
Effects reported include differences between the groups in 
mean changes (repeated measurements ANOVA);
 3
p-value for group effect; 
‡
based on 
logarithmic transformations 
TABLE 5. Amino acids levels (nmol/ mL) at baseline and at follow-up. 
  Baseline Follow-up Change     
  Mean (SD) Mean (SD) Mean (SD) P
1
 P
2
 
Alanine
‡
       
Placebo  278.9 (77.9) 329.1 (86.4) 50.2 (101) 0.002 0.006 
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Mastiha  343.9 (80.4) 324.5 (40.2) -19.4 (91.5) 0.418 
 
P
3
  < 0.001 0.767 
   
Glycine
‡
         
Placebo  212 (65.4) 237.4 (54.5) 25.4 (75.1) 0.008 0.115 
Mastiha  238.9 (55) 239.9 (25.5) 1 (52.7) 0.229 
 
P
3
 0.045 0.499 
   
α-Aminobutyric acid‡         
Placebo  13.9 (5.4) 16.4 (5.8) 2.5 (7.3) 0.018 0.401 
Mastiha  16 (6.5) 17.2 (6.6) 1.2 (7.1) 0.220 
 
P
3
 0.157 0.561 
   
Valine
‡
      
Placebo  311.7 (93.8) 363.4 (88) 51.7 (120.7) 0.001 0.047 
Mastiha  346.9 (75.7) 354.1 (39.6) 7.2 (80.7) 0.454  
 P
3
 0.045 0.848    
β-Aminobutyric acid‡      
Placebo  97.8 (2.3) 98.6 (2.6) 0.8 (3.5) 0.722 0.249 
Mastiha  98.1 (2.3) 104.6 (29) 6.5 (32.1) 0.157  
 P
3
 0.607 0.192    
Leucine
‡
      
Placebo  118.5 (44.2) 143.1 (41.7) 24.6 (60.7)  < 0.001 0.118 
Mastiha  127.5 (32) 135.9 (15.8) 8.4 (35.2) 0.137  
 P
3
 0.146 0.632    
Allo-isoleucine
‡
         
Placebo  50 (24.8) 58.6 (19.3) 8.6 (31.9) 0.004 0.122 
Mastiha  54.8 (18.9) 55.4 (6.9) 0.6 (21) 0.438 
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P
3
 0.146 0.698 
   
Isoleucine
‡
         
Placebo  58.8 (28.5) 67.3 (22.1) 8.5 (36.8) 0.011 0.159 
Mastiha  64.4 (21.6) 64.5 (8.2) 0.1 (24) 0.547 
 
P
3
 0.139 0.831 
   
Threonine
‡
       
Placebo  117.4 (41) 139 (46.1) 21.6 (56.6) 0.004 0.210 
Mastiha  124.9 (34.8) 131.2 (25.3) 6.3 (32.1) 0.238 
 
P
3
 0.321 0.591 
   
Serine
‡
       
Placebo  101.5 (29.6) 117.1 (32.6) 15.5 (34.4) 0.003 0.105 
Mastiha  110 (31) 111.1 (16.9) 1.2 (25.8) 0.458 
 
P
3
 0.238 0.550 
   
Proline
‡
       
Placebo  215.2 (65.5) 277.2 (73.4) 62 (85.6)  < 0.001 0.022 
Mastiha  269 (104.1) 277.8 (71.8) 8.8 (88.6) 0.241 
 
P
3
 0.018 0.922 
   
Asparagine
‡
       
Placebo  42.2 (12.4) 47.7 (11.8) 5.5 (15.3) 0.005 0.062 
Mastiha  47.7 (12.8) 47.1 (6.3) -0.7 (11.2) 0.844 
 
P
3
 0.050 0.918 
   
Thioproline
‡
         
Placebo  16.3 (4) 13.8 (2.9) -2.5 (5) 0.146 0.831 
Mastiha  17.8 (6.4) 14.6 (3.8) -3.2 (7.3) 0.081 
 
P
3
 0.856 0.406 
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Aspartic acid
‡
         
Placebo  7.7 (4.2) 7.4 (4.4) -0.3 (5.8) 0.547 0.964 
Mastiha  9.2 (5.9) 8.1 (4.4) -1.2 (8.6) 0.591 
 
P
3
 0.723 0.730 
   
Methionine     
Placebo  20.7 (8.7) 21.8 (7.8) 1.1 (11.2) 0.437 0.879 
Mastiha  20.9 (6) 21.7 (4.1) 0.8 (5) 0.576 
 
P
3
 0.928 0.923 
   
Hydroxyproline
‡
     
Placebo  17 (5.4) 18.1 (4.8) 1.1 (7.8) 0.207 0.074 
Mastiha  19.7 (5.7) 18.4 (6.8) -1.3 (6.6) 0.201 
 
P
3
 0.028 0.295 
   
Glutamic acid
‡
     
Placebo  18.2 (19.6) 22.2 (14.1) 4 (22.7) 0.143 0.688 
Mastiha  18.5 (11.5) 24.7 (12.3) 6.2 (15.8) 0.044 
 
P
3
 0.319 0.120 
   
Phenylalanine
‡
     
Placebo  62.4 (18.6) 74.1 (15.3) 11.7 (25.6) 0.001 0.188 
Mastiha  65.8 (13.2) 71.4 (8.1) 5.7 (16.6) 0.082 
 
P
3
 0.206 0.544 
   
Glutamine
‡
     
Placebo  355.9 (76.3) 405.5 (68) 49.6 (91.3) 0.003  < 0.001 
Mastiha  422 (90.1) 365.9 (59.7) -56 (102.3) 0.005 
 
P
3
 0.003 0.014 
   
Ornithine
‡
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Placebo  78.3 (27.1) 89.2 (27.3) 10.9 (38.7) 0.032 0.085 
Mastiha  89.8 (44) 82.3 (10.6) -7.4 (47.9) 0.778 
 
P
3
 0.163 0.279 
   
Lysine
‡
     
Placebo  177 (80.5) 187.2 (60.4) 10.2 (91.6) 0.100 0.098 
Mastiha  193.7 (68.4) 177.6 (21.8) -16.1 (73.2) 0.483 
 
P
3
 0.150 0.672 
   
Histidine
‡
     
Placebo  78.2 (23.4) 83.2 (17.7) 5 (27.5) 0.140 0.336 
Mastiha  78.2 (21.7) 76.8 (12.6) -1.4 (23.6) 0.903 
 
P
3
 0.894 0.135 
   
Tyrosine
‡
     
Placebo  50.6 (17.8) 65.9 (18.5) 15.4 (26.8)  < 0.001 0.043 
Mastiha  54.9 (15.3) 59.2 (10.5) 4.3 (20.2) 0.190 
 
P
3
 0.180 0.100 
   
Tryptophane
‡
     
Placebo  57.3 (16.1) 66.3 (16.5) 9 (26.2) 0.006 0.278 
Mastiha  59.1 (15.2) 62.1 (9.2) 3 (15.7) 0.207 
 
P
3
 0.575 0.275 
   
Cysteine
‡
     
Placebo  27 (2.6) 28.5 (3.1) 1.5 (3.9) 0.023 0.338 
Mastiha  27.1 (2.9) 27.6 (2.4) 0.6 (3.8) 0.340 
 
P
3
 0.972 0.203 
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1
p-value for time effect; 
2
Effects reported include differences between the groups in 
mean changes (repeated measurements ANOVA);
 3
p-value for group effect; 
‡
based on 
logarithmic transformations. 
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TABLE 6. Serum and faecal inflammatory markers at baseline and at follow up.  
 
Baseline Follow-up Change     
 
Mean (SD) Mean (SD) Mean (SD) P
1
 P
2
 
Serum CRP (mg/L)
‡
 
Placebo  4.4 (8.3) 5.2 (9.8) 0.8 (5.6) 0.161 0.859 
Mastiha  5.4 (9.1) 4.9 (5.5) -0.5 (8.6) 0.099 
 
P
3
 0.510 0.357 
   
Serum IL-6 (pg/ mL)
‡
 
Placebo  6.8 (16.6) 11.3 (12.7) 4.5 (12.4) 0.005 0.360 
Mastiha  6.5 (7.7) 10.3 (12.2) 3.8 (14) 0.093 
 
P
3
 0.279 0.916 
   
Serum IL-10 (pg/ mL)
‡
         
Placebo  7 (3.6) 6.2 (3) -0.8 (2.5) 0.222 0.770 
Mastiha  7.2 (10.1) 5.8 (3) -1.4 (9.3) 0.416 
 
P
3
 0.334 0.465 
   
Faecal lysozyme (μg/g)‡ 
Placebo  12.2 (9.8) 9.1 (6.1) -3.1 (12) 0.155 0.614 
Mastiha  15.7 (23.6) 9.4 (3.3) -6.3 (25.6) 0.472  
P
3
 0.973 0.359    
Faecal calprotectin (μg/g)‡ 
Placebo  940.9 (988.8) 5221.3 (18634.4) 4280.3 (18705.7) 0.002 0.117 
Mastiha  1396.6 (4547.6) 977.63 (960.3) -419.0(4756.2) 0.145  
P
3
 0.817 0.026    
Faecal lactoferrin (μg/g)‡ 
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Placebo  112.4 (210.2) 141.4 (155.5) 29 (267.5) 0.035 0.419 
Mastiha  65.7 (98.3) 86.12 (143.7) -20.4(155.5) 0.060  
P
3
 0.715 0.156    
1
p-value for time effect; 
2
Effects reported include differences between the groups in 
mean changes (repeated measurements ANOVA);
 3
p-value for group effect; 
‡
based on 
logarithmic transformations. 
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Graphical-Abstract. 
 
 
